Zealand Pharma CEO undeterred by lower than expected Zegalogue sales

Emmanuel Dulac, CEO of Zealand Pharma, is not disappointed that the biotech company's blood sugar pen Zegalogue has generated worse sales figures than expected for 2021. The CEO highlights that the bar was set high.

Zealand Pharma CEO Emmanuel Dulac | Photo: Stine Bidstrup/ERH

Zegalogue, an emergency auto-injector pen and Zealand Pharma's first independently launched product, entered the US market in June.

CEO Emmanuel Dulac is not disappointed by the launch, despite the fact that the company downgraded expectations for 2021 product sales revenue due to worse sales than expected for the product.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs